Literature DB >> 10870094

Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice.

G O Udeani1, G M Zhao, Y Geun Shin, B P Cooke, J Graham, C W Beecher, A D Kinghorn, J M Pezzuto.   

Abstract

Betulinic acid is a naturally occurring pentacyclic triterpenoid. Betulinic acid has recently been selected by the National Cancer Institute for addition into the RAID (Rapid Access to Intervention in Development) programme. The agent exhibits potential anti-tumour activity and functions in this regard via apoptosis. The objective of the present study was to determine the pharmacokinetics of betulinic acid in CD-1 mice. Serum samples were obtained at designed times after a single 250 or 500 mg/kg intraperitoneal (IP) dose of betulinic acid. Tissue samples (skin, heart, liver, spleen, kidney, lung, brain, colon, caecum, ovary, uterus, thymus, lymph node, bladder, perirenal fat, mammary gland and small intestine) were collected after betulinic acid administration (500 mg/kg). Betulinic acid was extracted with methylene chloride and quantitatively analysed by HPLC/MS. Oleanolic acid and madecassic acid were used as internal standards. Pharmacokinetic parameters were calculated using the WinNonlin pharmacokinetic software package. A two-compartment, first-order model was selected for pharmacokinetic modelling. The results showed that after IP 250 and 500 mg/kg betulinic acid, the serum concentrations reached peaks at 0.15 and 0.23 h, respectively. The 250 and 500 mg/kg above betulinic acid IP doses were found to have elimination half-lives of 11.5 and 11.8 h and total clearances of 13.6 and 13.5 L/kg/h, respectively. The pharmacokinetic parameters observed for IP betulinic acid 500 mg/kg in the skin of mice were as follows: k(a) (h(-1)) 0.257, k(10) (h(-1)) 0.234, t(1/2(alpha)) (h) 2.63, t(1/2(beta)) (h) 20.2, V (L/kg) 0.61, AUC (microg/h/mL) 3504, T(max) (h) 3.90 and C(max) (microg/mL) 300.9. The distribution of betulinic acid in tissues at 24 h post-IP administration in a descending order was as follows: perirenal fat, ovary, spleen, mammary gland, uterus, bladder, lymph node, liver, small intestine, caecum, lung, thymus, colon, kidney, skin, heart and brain. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10870094     DOI: 10.1002/1099-081x(199911)20:8<379::aid-bdd198>3.0.co;2-c

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  17 in total

1.  New ionic derivatives of betulinic acid as highly potent anti-cancer agents.

Authors:  Challa Suresh; Hua Zhao; Angelique Gumbs; Chellu S Chetty; Himangshu S Bose
Journal:  Bioorg Med Chem Lett       Date:  2011-12-28       Impact factor: 2.823

2.  Betulinic acid suppresses constitutive and TNFalpha-induced NF-kappaB activation and induces apoptosis in human prostate carcinoma PC-3 cells.

Authors:  Thangaiyan Rabi; Sanjeev Shukla; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2008-12       Impact factor: 4.784

3.  Sensitization for anticancer drug-induced apoptosis by betulinic Acid.

Authors:  Simone Fulda; Klaus-Michael Debatin
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

4.  Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.

Authors:  Hifzur Rahman Siddique; Shrawan Kumar Mishra; R Jeffery Karnes; Mohammad Saleem
Journal:  Clin Cancer Res       Date:  2011-06-28       Impact factor: 12.531

5.  Co-administration of betulinic acid and methamphetamine causes toxicity to dopaminergic and serotonergic nerve terminals in the striatum of late adolescent rats.

Authors:  Bryan Killinger; Mrudang Shah; Anna Moszczynska
Journal:  J Neurochem       Date:  2013-12-03       Impact factor: 5.372

6.  Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity.

Authors:  Praveen Rajendran; Manu Jaggi; Manoj K Singh; Rama Mukherjee; Anand C Burman
Journal:  Invest New Drugs       Date:  2007-09-13       Impact factor: 3.850

Review 7.  New Botanical Anxiolytics for Use in Companion Animals and Humans.

Authors:  Rui Liu; Fida Ahmed; Christian Cayer; Martha Mullally; Ana Francis Carballo; Marco Otarola Rojas; Mario Garcia; John Baker; Aleksandar Masic; Pablo E Sanchez; Luis Poveda; Zul Merali; Tony Durst; John T Arnason
Journal:  AAPS J       Date:  2017-09-11       Impact factor: 4.009

8.  Safety evaluation of a new anxiolytic product containing botanicals Souroubea spp. and Platanus spp. in dogs.

Authors:  Aleksandar Masic; Rui Liu; Kristen Simkus; Jeff Wilson; John Baker; Pablo Sanchez; Ammar Saleem; Cory C Harris; Tony Durst; John T Arnason
Journal:  Can J Vet Res       Date:  2018-01       Impact factor: 1.310

9.  Inhibition of phosphotidylinositol-3 kinase pathway by a novel naphthol derivative of betulinic acid induces cell cycle arrest and apoptosis in cancer cells of different origin.

Authors:  R Majeed; A Hamid; P L Sangwan; P K Chinthakindi; S Koul; S Rayees; G Singh; D M Mondhe; M J Mintoo; S K Singh; S K Rath; A K Saxena
Journal:  Cell Death Dis       Date:  2014-10-09       Impact factor: 8.469

10.  Betulinic Acid for cancer treatment and prevention.

Authors:  Simone Fulda
Journal:  Int J Mol Sci       Date:  2008-06-27       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.